Background No new agent has improved overall survival in patients with unresectable or
metastatic urothelial carcinoma when added to first-line cisplatin-based chemotherapy …

Cystectomy is a standard treatment for muscle-invasive bladder cancer (MIBC), but it is life-
altering. We initiated a phase 2 study in which patients with MIBC received four cycles of …

Management of first-line advanced urothelial carcinoma (UC) has consisted during the past
three decades in the administration of platinum-based chemotherapy followed by …

Background Combinations of immune checkpoint inhibitors (ICI) with platinum-based
chemotherapy (PlatinumCT) or with another ICI in the first-line setting for patients with …

Cisplatin-based chemotherapy has been associated with durable disease control in a small
subset of patients with metastatic urothelial cancer. However, the mechanistic basis for this …

Background IMvigor130 demonstrated statistically significant investigator-assessed
progression-free survival benefit with first-line atezolizumab plus platinum-based …

Background The primary analysis of IMvigor130 showed a significant progression-free
survival benefit with first-line atezolizumab plus platinum-based chemotherapy (group A) …

Durable responses with first-line platinum-based chemotherapy for advanced-stage
urothelial carcinoma are rare, and patient outcomes are poor. Recently, CheckMate 901 …

Opinion statement The treatment landscape for urothelial cancer has changed dramatically
in the last 10 years, with the approval of several new treatments. At the same time, profiling …

Background Radiation may improve the efficacy of immune checkpoint inhibition. This study
investigates the combination of pembrolizumab and chemoradiation (CRT) for muscle …